Gilead targets remdesivir supply for two million COVID-19 patients by year-end
The company also said it hoped to start trials in August of an easier-to-use inhaled version of the medicine, currently…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Gilead Sciences
Gilead to commence trials of inhaled remdesivir
The CEO informs that the company aims to enable easier administration outside the hospital at earlier stages of the disease with…
Double digit MCap growth in 2019 for 14 of top 20 pharma companies: GlobalData
Among the positive performances were Takeda Pharmaceutical and Daiichi Sankyo, which reported more than 100 per cent YoY growth in…
Centre clarifies reasons for delay in approvals for remdesivir
Informs that it is awaiting data on some crucial parameters from companies that have applied for manufacturing and marketing…
BDR Pharma urges regulators to expedite manufacturing, marketing license process for remdesivir
The company informed that central and state regulatory authorities have carried out an inspection of its API manufacturing site in…
Dr Reddy’s signs licensing agreement with Gilead Sciences for remdesivir
Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug and needs to do the manufacturing scale-up…
Zydus Cadila inks licensing pact with Gilead for remdesivir
The licence is royalty-free until another pharma product or vaccine is approved for the treatment or prevention of COVID-19 by the…
Remdesivir in India: An unfolding story
Remdesivir has emerged as one of the most promising drug candidates for the treatment of COVID-19. But, is it affordable for…
Gilead’s remdesivir shows modest improvement in moderate COVID-19 patients
Remdesivir, which is administered intravenously in hospital, is the first drug to show improvement in COVID-19 patients in formal…
Remdesivir approved for use in treatment of severe COVID-19 patients
The injectable medicine has been allowed for administration as part of a maximum five-day regimen